Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. <...> Gratwohl A., Hermans J., Niederwieser D., Frassoni F., Arcese W., Gahrton G., et al. <...> Bone marrow transplantation for chronic myeloid leukemia: long-term results Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. <...> Quintбs-Cardama A., Kantarjian H.M., Garcia-Manero G., O’Brien S., Faderl S., Ravandi F., et al. <...> A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. <...> Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. <...> Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. <...> Imatinib mesylate (STI571) therapy for Philadelphia chromosomepositive chronic myelogenous leukemia in blast phase. <...> Palandri F., Castagnetti F., Testoni N., Luatti S., Marzocchi G., Bassi S., et al.; GIMEMA Working Party on Chronic Myeloid Leukemia. <...> Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <...> Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <...> Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. <...> Dasatinib in imatinibresistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. <...> ОСОБЕННОСТИ ДИАГНОСТИКИ СИНДРОМА БЕРНАРА–СУЛЬЕ ФГБУ «Гематологический научный центр Минздрава России», 126167, г. <...> Москва, Россия патогенеза СБС является дефицит или дефект гликопротеинового комплекса GPIb-IX–V на поверхности тромбоцитов – главного тромбоцитарного рецептора для фактора Виллебранда (vWF). <...> При связывании vWF с комплексом GPIb-IX–V происходят инициация первичного гемостаза и обеспечение адгезии тромбоцитов в месте повреждения сосуда. <...> К <...>